Bruker reports Q2 EPS 32c, consensus 42c

Reports Q2 revenue $797.4M, consensus $810.15M. Frank Laukien, Bruker’s (BRKR) president and CEO, commented: “Life-science research instruments demand is under pressure at the moment. Our second quarter came in below expectations, as we experienced challenging demand conditions in the US academic market, as well as in biopharma and industrial markets. Tariffs and a stiff currency headwind could not yet be compensated for by our mitigating price, supply chain and cost actions in the second quarter. We are lowering our financial guidance for FY 2025, while we gain improved visibility into US academic funding trends, China stimulus, finalized tariffs, as well as into the timing of a recovery in biopharma drug discovery and industrial research instruments demand.”